NetScientific PLC - London-based life sciences and sustainability technology investment firm - Reports second-quarter results from portfolio firm, PDS Biotechnology Corp. Net loss for three months to June 30 was USD5.8 million, or USD0.20 per basic share, widened from USD600,000, or USD0.03, a year before. "The higher net loss reported for the three months ended June 2022 is primarily due to additional costs for expansion of the company's research and development, including costs associated with our ongoing clinical trials, additional general and administrative costs, and lower income tax benefit," it says. PDS's cash balance at June 30 stands at USD53.0 million. Netscientific holds 47% stake in PDS.
Current stock price: 64.00 pence
12-month change: down 45%
By Lucy Heming; lucyheming@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.
Netscientific (NSCI)